Rheumatoid Arthritis Drugs include prescription and OTC.
The increasing prevalence of arthritis, the increasing acceptance of biopharmaceuticals, and the development of clear regulatory guidelines are major trends that are expected to trigger market growth.

The global Rheumatoid Arthritis Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Rheumatoid Arthritis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rheumatoid Arthritis Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Rheumatoid Arthritis Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Rheumatoid Arthritis Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AbbVie
Amgen
Bayer
Biogen
Boehringer Ingelheim
Bristol-Myers Squibb
F. Hoffmann-La Roche
Johnson and Johnson
Merck
Mitsubishi Tanabe Pharma
Novartis
Pfizer
UCB S.A

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Prescription Drugs
Over-the-counter Drugs

Segment by Application
Hospital
Clinic
Nursing home
Other